Maria Zambon

Maria Zambon's AcademicInfluence.com Rankings

Maria Zambon

Biology

#7590

Historical Rank

Virology

#112

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Maria Zambon Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Maria Caterina Zambon FMedSci FRCPath, is a British virologist, director of reference microbiology for Public Health England and a professor. Her main research areas include influenza vaccination and influenza hemagglutination inhibition.

(See a Problem?)

Maria Zambon's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR (2020) (5805)
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant (2021) (1868)
Commentary: Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group (2013) (1101)
Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome (2003) (1016)
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant (2022) (995)
Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study (2010) (779)
Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020 (2020) (688)
Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. (2012) (582)
Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion (2019) (548)
Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. (2012) (473)
Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza (2001) (471)
Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study (2020) (459)
Mapping the human genetic architecture of COVID-19 (2021) (455)
Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study (2021) (444)
COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study (2021) (423)
Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial (2006) (418)
Oseltamivir-Resistant Influenza Virus A (H1N1), Europe, 2007–08 Season (2009) (416)
SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) (2021) (415)
SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) (2021) (415)
Detection of Influenza Viruses Resistant to Neuraminidase Inhibitors in Global Surveillance during the First 3 Years of Their Use (2006) (379)
Comparative community burden and severity of seasonal and pandemic influenza: results of the Flu Watch cohort study (2014) (356)
Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. (2008) (334)
Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. (2008) (334)
State of Knowledge and Data Gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Humans (2013) (326)
Multiplex PCR for Typing and Subtyping Influenza and Respiratory Syncytial Viruses (1998) (320)
Neuraminidase Sequence Analysis and Susceptibilities of Influenza Virus Clinical Isolates to Zanamivir and Oseltamivir (2003) (313)
Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines (2022) (307)
Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein (2020) (300)
Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. (2005) (296)
Late Ebola virus relapse causing meningoencephalitis: a case report (2016) (278)
Infection of Human Airway Epithelium by Human and Avian Strains of Influenza A Virus (2006) (260)
Epidemiology and pathogenesis of influenza. (1999) (259)
Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine (2009) (253)
Effectiveness of COVID-19 vaccines against the B.1.617.2 variant (2021) (228)
The mechanism of resistance to favipiravir in influenza (2018) (219)
Evaluation of Neuraminidase Enzyme Assays Using Different Substrates To Measure Susceptibility of Influenza Virus Clinical Isolates to Neuraminidase Inhibitors: Report of the Neuraminidase Inhibitor Susceptibility Network (2003) (216)
Natural T Cell-mediated Protection against Seasonal and Pandemic Influenza. Results of the Flu Watch Cohort Study. (2015) (215)
Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus (2015) (209)
Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. (2012) (195)
Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. (2004) (192)
Molecular basis of resistance of influenza A viruses to amantadine. (1986) (190)
Confronting the avian influenza threat: vaccine development for a potential pandemic (2004) (189)
The pathogenesis of influenza in humans (2001) (188)
Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma (2000) (188)
Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. (2009) (184)
Serological analysis of serum samples from humans exposed to avian H7 influenza viruses in Italy between 1999 and 2003. (2005) (178)
Diagnosis of influenza in the community: relationship of clinical diagnosis to confirmed virological, serologic, or molecular detection of influenza. (2001) (177)
Multiplex reverse transcription-PCR for surveillance of influenza A and B viruses in England and Wales in 1995 and 1996 (1997) (175)
Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. (2003) (168)
Global outbreak of severe Mycobacterium chimaera disease after cardiac surgery: a molecular epidemiological study. (2017) (166)
Longitudinally Profiling Neutralizing Antibody Response to SARS Coronavirus with Pseudotypes (2005) (162)
Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin (2003) (161)
Position statement: global neuraminidase inhibitor susceptibility network. (2001) (159)
Pandemic Influenza A (H1N1) 2009 and mortality in the United Kingdom: risk factors for death, April 2009 to March 2010. (2010) (158)
Human Metapneumovirus as a Cause of Community-Acquired Respiratory Illness (2002) (156)
Epidemiological and virological characteristics of influenza B: results of the Global Influenza B Study (2015) (153)
Antibody-based assay discriminates Zika virus infection from other flaviviruses (2017) (150)
A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. (2009) (150)
Molecular diagnosis of influenza (2002) (150)
DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. (2009) (148)
Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection. (2013) (146)
Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial (2003) (146)
Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study), England: June to November 2020 (2021) (144)
Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results (2016) (142)
A sensitive retroviral pseudotype assay for influenza H5N1‐neutralizing antibodies (2007) (140)
Evidence of person-to-person transmission within a family cluster of novel coronavirus infections, United Kingdom, February 2013. (2013) (140)
COVID-19 in children: analysis of the first pandemic peak in England (2020) (137)
Reproducibility of Serologic Assays for Influenza Virus A (H5N1) (2009) (137)
Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study (2021) (136)
Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events (2016) (127)
Interactions between SARS-CoV-2 and influenza, and the impact of coinfection on disease severity: a test-negative design (2020) (124)
Laboratory diagnosis of SARS. (2004) (119)
Outbreak of low pathogenicity H7N3 avian influenza in UK, including associated case of human conjunctivitis. (2006) (117)
Insidious Risk of Severe Mycobacterium chimaera Infection in Cardiac Surgery Patients (2017) (115)
The duration and magnitude of influenza epidemics: A study of surveillance data from sentinel general practices in England, Wales and the Netherlands (1999) (114)
Evolutionary Dynamics of Local Pandemic H1N1/2009 Influenza Virus Lineages Revealed by Whole-Genome Analysis (2011) (110)
Assessment of baseline age-specific antibody prevalence and incidence of infection to novel influenza A/H1N1 2009. (2010) (109)
Rates of hospitalisation for influenza, respiratory syncytial virus and human metapneumovirus among infants and young children. (2006) (109)
Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses. (2014) (108)
Risk and protective factors for meningococcal disease in adolescents: matched cohort study (2006) (108)
Uptake and impact of vaccinating school age children against influenza during a season with circulation of drifted influenza A and B strains, England, 2014/15. (2015) (106)
Tracking SARS-CoV-2 in Sewage: Evidence of Changes in Virus Variant Predominance during COVID-19 Pandemic (2020) (104)
Phase I Evaluation of Intranasal Trivalent Inactivated Influenza Vaccine with Nontoxigenic Escherichia coli Enterotoxin and Novel Biovector as Mucosal Adjuvants, Using Adult Volunteers (2006) (104)
Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 end of season results. (2015) (103)
Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus, United Kingdom, winter 2010/11. (2011) (102)
Evaluation of Serologic and Antigenic Relationships Between Middle Eastern Respiratory Syndrome Coronavirus and Other Coronaviruses to Develop Vaccine Platforms for the Rapid Response to Emerging Coronaviruses (2013) (102)
Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial. (2011) (101)
Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. (2008) (100)
Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study (2021) (98)
Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 mid-season results. (2015) (97)
Uptake and impact of a new live attenuated influenza vaccine programme in England: early results of a pilot in primary school-age children, 2013/14 influenza season. (2014) (94)
Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK (2021) (94)
Changing composition of SARS-CoV-2 lineages and rise of Delta variant in England (2021) (93)
Contribution of RSV to bronchiolitis and pneumonia-associated hospitalizations in English children, April 1995–March 1998 (2002) (91)
Estimating influenza vaccine effectiveness using routinely collected laboratory data (2009) (90)
Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. (2008) (89)
Subcellular localization of the severe acute respiratory syndrome coronavirus nucleocapsid protein. (2005) (88)
Low effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 mid-season results. (2015) (87)
Seroconversion after influenza vaccination in patients with lung cancer (1999) (86)
Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. (2011) (86)
Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individuals. (2008) (85)
Emergence of influenza A H1N2 reassortant viruses in the human population during 2001. (2002) (85)
Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996–2007 (2009) (85)
Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. (2008) (85)
Antibody responses to vaccinations given within the first two years after transplant are similar between autologous peripheral blood stem cell and bone marrow transplant recipients (2001) (84)
Accumulation of Human-Adapting Mutations during Circulation of A(H1N1)pdm09 Influenza Virus in Humans in the United Kingdom (2014) (81)
Pandemic (H1N1) 2009 influenza in the UK: clinical and epidemiological findings from the first few hundred (FF100) cases (2010) (81)
Rapid Quantitation of Neuraminidase Inhibitor Drug Resistance in Influenza virus Quasispecies (2008) (81)
Open source clinical science for emerging infections (2013) (80)
Investigation of SARS-CoV-2 outbreaks in six care homes in London, April 2020 (2020) (80)
Molecular Epidemiology of Two Consecutive Outbreaks of Parainfluenza 3 in a Bone Marrow Transplant Unit (1998) (80)
Characterisation of the transcriptome and proteome of SARS-CoV-2 using direct RNA sequencing and tandem mass spectrometry reveals evidence for a cell passage induced in-frame deletion in the spike glycoprotein that removes the furin-like cleavage site (2020) (78)
London 2012 Olympic and Paralympic Games: public health surveillance and epidemiology (2014) (78)
Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study (2021) (77)
The epidemiological signature of influenza B virus and its B/Victoria and B/Yamagata lineages in the 21st century (2019) (76)
Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14–16 June 2010 (2013) (76)
Convalescent plasma therapy for the treatment of patients with COVID‐19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels (2020) (76)
Restrictions to the Adaptation of Influenza A Virus H5 Hemagglutinin to the Human Host (2004) (74)
Effectiveness of seasonal influenza vaccination during pregnancy in preventing influenza infection in infants, England, 2013/14. (2014) (74)
Effectiveness of seasonal 2010/11 and pandemic influenza A(H1N1)2009 vaccines in preventing influenza infection in the United Kingdom: mid-season analysis 2010/11. (2011) (73)
Reproducibility of serology assays for pandemic influenza H1N1: collaborative study to evaluate a candidate WHO International Standard. (2012) (72)
Epidemiological features of parainfluenza virus infections: Laboratory surveillance in England and Wales, 1975–1997 (1999) (72)
Response to influenza immunisation during treatment for cancer (2001) (70)
High prevalence of SARS-CoV-2 antibodies in care homes affected by COVID-19: Prospective cohort study, England (2020) (69)
Emergence of a Novel Coronavirus (COVID-19): Protocol for Extending Surveillance Used by the Royal College of General Practitioners Research and Surveillance Centre and Public Health England (2020) (68)
Increased risk of SARS-CoV-2 infection in staff working across different care homes: enhanced CoVID-19 outbreak investigations in London care Homes (2020) (68)
The Evolution of Norovirus, the “Gastric Flu” (2008) (67)
A Mouse Model for Betacoronavirus Subgroup 2c Using a Bat Coronavirus Strain HKU5 Variant (2014) (66)
Population estimates of persons presenting to general practitioners with influenza-like illness, 1987–96: a study of the demography of influenza-like illness in sentinel practice networks in England and Wales, and in The Netherlands (2000) (66)
Virological analysis of fatal influenza cases in the United Kingdom during the early wave of influenza in winter 2010/11. (2011) (66)
Temporal Patterns of Influenza A and B in Tropical and Temperate Countries: What Are the Lessons for Influenza Vaccination? (2016) (65)
Current research on respiratory viral infections: Fourth International Symposium (2001) (61)
SARS-CoV-2 infection and transmission in primary schools in England in June–December, 2020 (sKIDs): an active, prospective surveillance study (2021) (60)
Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020 (2020) (60)
Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups (2022) (59)
Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2012/13 end of season results. (2014) (59)
A new laboratory-based surveillance system (Respiratory DataMart System) for influenza and other respiratory viruses in England: results and experience from 2009 to 2012. (2014) (58)
Neuraminidase Inhibitor Susceptibility Network Position Statement: Antiviral Resistance in Influenza A/H5N1 Viruses (2006) (58)
End-of-season influenza vaccine effectiveness in adults and children, United Kingdom, 2016/17 (2017) (57)
Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom (2012) (57)
Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK (2021) (56)
Improving influenza vaccine virus selectionReport of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14–16 June 2010 (2011) (56)
Monitoring the emergence of community transmission of influenza A/H1N1 2009 in England: a cross sectional opportunistic survey of self sampled telephone callers to NHS Direct (2009) (56)
Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020 (2020) (56)
SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus (2020) (56)
Mycobacterium chimaera infection following cardiac surgery in the United Kingdom: clinical features and outcome of the first 30 cases. (2018) (55)
Changes in in vitro susceptibility of influenza A H3N2 viruses to a neuraminidase inhibitor drug during evolution in the human host. (2004) (55)
Transmission dynamics of COVID-19 in household and community settings in the United Kingdom, January to March 2020 (2020) (55)
Alterations in Receptor Binding Properties of Recent Human Influenza H3N2 Viruses Are Associated with Reduced Natural Killer Cell Lysis of Infected Cells (2007) (53)
Influenza among U.K. Pilgrims to Hajj, 2003 (2004) (53)
An H7N1 Influenza Virus Vaccine Induces Broadly Reactive Antibody Responses against H7N9 in Humans (2014) (52)
Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants. (2008) (52)
Influenza A antigen exposure selects dominant Vbeta17+ TCR in human CD8+ cytotoxic T cell responses. (2001) (51)
Harmonizing influenza primary-care surveillance in the United Kingdom: piloting two methods to assess the timing and intensity of the seasonal epidemic across several general practice-based surveillance schemes (2014) (50)
Distribution of influenza virus types by age using case-based global surveillance data from twenty-nine countries, 1999-2014 (2018) (49)
Influenza AH1N2 Viruses, United Kingdom, 2001–02 Influenza Season (2003) (49)
Antibodies to SARS-CoV-2 protect against re-infection during outbreaks in care homes, September and October 2020 (2021) (49)
Evolutionary Pathways of the Pandemic Influenza A (H1N1) 2009 in the UK (2011) (49)
COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study (2021) (49)
Combined PCR-Heteroduplex Mobility Assay for Detection and Differentiation of Influenza A Viruses from Different Animal Species (2001) (48)
The epidemiology of influenza (2002) (48)
Use of antiviral drugs to reduce household transmission of pandemic (H1N1) 2009, United Kingdom. (2011) (48)
SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. (2020) (47)
Design and Validation of an H5 TaqMan Real-Time One-Step Reverse Transcription-PCR and Confirmatory Assays for Diagnosis and Verification of Influenza A Virus H5 Infections in Humans (2007) (46)
Influenza immunisation in children with solid tumours. (2005) (44)
Parvovirus B19 outbreak on an adult ward (1994) (44)
Randomised controlled trial and health economic evaluation of the impact of diagnostic testing for influenza, respiratory syncytial virus and Streptococcus pneumoniae infection on the management of acute admissions in the elderly and high-risk 18- to 64-year-olds. (2014) (43)
Determining the Mutation Bias of Favipiravir in Influenza Virus Using Next-Generation Sequencing (2018) (43)
Disparities in the excess risk of mortality in the first wave of COVID-19: Cross sectional study of the English sentinel network (2020) (43)
Observational study to investigate vertically acquired passive immunity in babies of mothers vaccinated against H1N1v during pregnancy. (2010) (43)
Rapid Increase of SARS-CoV-2 Variant B.1.1.7 Detected in Sewage Samples from England between October 2020 and January 2021 (2021) (42)
Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study (2021) (42)
Respiratory syncytial virus: an underestimated cause of respiratory infection, with prospects for a vaccine. (1999) (41)
Molecular analysis of an outbreak of influenza in the United Kingdom (1997) (41)
Urgent challenges in implementing live attenuated influenza vaccine. (2018) (41)
Comment on “Seroevidence for H5N1 Influenza Infections in Humans: Meta-Analysis” (2012) (40)
Seasonality and immunity to laboratory-confirmed seasonal coronaviruses (HCoV-NL63, HCoV-OC43, and HCoV-229E): results from the Flu Watch cohort study. (2020) (40)
M1-like monocytes are a major immunological determinant of severity in previously healthy adults with life-threatening influenza (2017) (38)
Mortality Attributable to Influenza in England and Wales Prior to, during and after the 2009 Pandemic (2013) (38)
A cell‐based H7N1 split influenza virion vaccine confers protection in mouse and ferret challenge models (2009) (37)
The Early Transmission Dynamics of H1N1pdm Influenza in the United Kingdom. (2009) (36)
Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England (2021) (36)
Effectiveness of seasonal 2012/13 vaccine in preventing laboratory-confirmed influenza infection in primary care in the United Kingdom: mid-season analysis 2012/13. (2013) (36)
The Oxford Royal College of General Practitioners Clinical Informatics Digital Hub: Protocol to Develop Extended COVID-19 Surveillance and Trial Platforms (2020) (35)
Transmission of paediatric respiratory syncytial virus and influenza in the wake of the COVID-19 pandemic (2021) (35)
Antiviral drug resistance (1996) (35)
Serum IgG titres, but not avidity, correlates with neutralizing antibody response after H5N1 vaccination. (2014) (35)
Pandemic ( H 1 N 1 ) 2009 influenza in the UK : clinical and epidemiological findings from the first few hundred ( FF 100 ) cases (2010) (35)
Probable Vertical Transmission of SARS-CoV-2 Infection (2020) (34)
SARS transmission in Vietnam outside of the health-care setting (2006) (34)
Fatal Cases of Influenza A in Childhood (2009) (34)
Effects of seasonal and pandemic influenza on health‐related quality of life, work and school absence in England: Results from the Flu Watch cohort study (2018) (34)
Excess mortality in the first COVID pandemic peak: cross-sectional analyses of the impact of age, sex, ethnicity, household size, and long-term conditions in people of known SARS-CoV-2 status in England (2020) (34)
Influenza surveillance in England and Wales: October 1996 to June 1997. (1997) (33)
End of season influenza vaccine effectiveness in adults and children in the United Kingdom in 2017/18 (2019) (33)
Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome (2016) (33)
Influenza imprinting in childhood and the influence on vaccine response later in life (2019) (33)
Generation of candidate human influenza vaccine strains in cell culture – rehearsing the European response to an H7N1 pandemic threat (2007) (33)
Influenza-related hospitalizations among young children in Leicestershire (2003) (32)
Linking syndromic surveillance with virological self-sampling (2007) (32)
Oseltamivir-Resistant Pandemic (H1N1) 2009 Virus Infection in England and Scotland, 2009–2010 (2011) (32)
Seroprevalence of Influenza A(H1N1)pdm09 Virus Antibody, England, 2010 and 2011 (2012) (32)
Near patient testing for influenza in children in primary care: comparison with laboratory test (2003) (31)
Guidance on the development and validation of diagnostic tests that depend on nucleic acid amplification and detection. (2013) (31)
Snapshot PCR surveillance for SARS-CoV-2 in hospital staff in England (2020) (31)
Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations. (2009) (30)
Seasonality and immunity to laboratory-confirmed seasonal coronaviruses (HCoV-NL63, HCoV-OC43, and HCoV-229E): results from the Flu Watch cohort study (2020) (30)
Influenza virological surveillance in children: The use of the Quickvue rapid diagnostic test (2004) (30)
Uptake and impact of vaccinating primary school-age children against influenza: experiences of a live attenuated influenza vaccine programme, England, 2015/16. (2018) (30)
Cohort Profile: The Flu Watch Study (2016) (30)
Multiple Actions of Amantadine Against Influenza Viruses (1984) (29)
Cleavage and Serum Reactivity of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein (2004) (29)
Different diagnostic methods for detection of influenza epidemics (2000) (29)
COVID-19 in Great Britain: epidemiological and clinical characteristics of the first few hundred (FF100) cases: a descriptive case series and case control analysis (2020) (28)
Immunogenicity and safety of a two-dose schedule of whole-virion and AS03(A)-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial (2011) (28)
Influenza (1890) (28)
End of season influenza vaccine effectiveness in primary care in adults and children in the United Kingdom in 2018/19. (2020) (27)
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape. (2022) (27)
Influenza-associated mortality in hospital care: a retrospective cohort study of risk factors and impact of oseltamivir in an English teaching hospital, 2016 to 2017 (2019) (27)
Modelling hospital admissions for lower respiratory tract infections in the elderly in England (2006) (27)
Toward unified molecular surveillance of RSV: A proposal for genotype definition (2020) (27)
Influenza and other emerging respiratory viruses (2013) (26)
Influenza antiviral susceptibility monitoring activities in relation to national antiviral stockpiles in Europe during the winter 2006/2007 season. (2007) (25)
Enhanced MERS Coronavirus Surveillance of Travelers from the Middle East to England (2014) (25)
Influenza (1925) (25)
Influenza surveillance in England and Wales: October 1999 to May 2000. (2000) (24)
Comparability of six different immunoassays measuring SARS‐CoV‐2 antibodies with neutralizing antibody levels in convalescent plasma: From utility to prediction (2021) (24)
Personal Protective Equipment and Risk for Avian Influenza (H7N3) (2009) (23)
Development of vaccines against common colds. (2002) (23)
Response to influenza virus vaccination in vertical HIV infection (1997) (23)
Infection and transmission of SARS-CoV-2 in London care homes reporting no cases or outbreaks of COVID-19: Prospective observational cohort study, England 2020 (2021) (22)
Influenza surveillance in the United Kingdom: October 2001 to May 2002 (2002) (21)
Establishment of a UK National Influenza H5 Laboratory Network. (2007) (21)
Analysis of influenza A H3N2 strains isolated in England during 1995–1996 using polymerase chain reaction restriction (1997) (21)
Progression of whole-blood transcriptional signatures from interferon-induced to neutrophil-associated patterns in severe influenza (2018) (21)
Emergence of SARS-CoV-2 Alpha (B.1.1.7) variant, infection rates, antibody seroconversion and seroprevalence rates in secondary school students and staff: Active prospective surveillance, December 2020 to March 2021, England (2021) (20)
Hand Hygiene Practices and the Risk of Human Coronavirus Infections in a UK Community Cohort. (2020) (20)
Pandemic risks from bird flu (2004) (20)
Patterns of systemic and local inflammation in patients with asthma hospitalised with influenza (2019) (20)
The role of viral genomics in understanding COVID-19 outbreaks in long-term care facilities (2021) (20)
Leveraging the Global Influenza Surveillance and Response System for global respiratory syncytial virus surveillance—opportunities and challenges (2019) (19)
Influenza Virus with Increased pH of Hemagglutinin Activation Has Improved Replication in Cell Culture but at the Cost of Infectivity in Human Airway Epithelium (2019) (19)
Nucleic Acid Dipstick Test for Molecular Diagnosis of Pandemic H1N1 (2010) (19)
A comparison of two molecular methods for diagnosing leptospirosis from three different sample types in patients presenting with fever in Laos (2017) (19)
Uptake and effectiveness of influenza vaccine in those aged 65 years and older in the United Kingdom, influenza seasons 2010/11 to 2016/17 (2018) (19)
M1-like monocytes are a major immunological determinant of severity in previously healthy adults with life-threatening influenza. (2017) (18)
Self-sampling for community respiratory illness: a new tool for national virological surveillance. (2015) (18)
Antiviral drug profile of seasonal influenza viruses circulating in Portugal from 2004/2005 to 2008/2009 winter seasons. (2010) (18)
VII International Symposium on Respiratory Viral Infections (2005) (17)
Fatal Cases of Influenza A(H3N2) in Children: Insights from Whole Genome Sequence Analysis (2012) (17)
The value of open-source clinical science in pandemic response: lessons from ISARIC (2021) (17)
The potential risks and impact of the start of the 2015–2016 influenza season in the WHO European Region: a rapid risk assessment (2016) (17)
Influenza (2022) (17)
Sentinel surveillance of influenza in Europe 1997-1998. (1998) (17)
Developments in the treatment of severe influenza: lessons from the pandemic of 2009 and new prospects for therapy (2014) (16)
Onset and window of SARS-CoV-2 infectiousness and temporal correlation with symptom onset: a prospective, longitudinal, community cohort study (2022) (16)
The UK's multidisciplinary response to an Ebola epidemic. (2017) (16)
Effectiveness of influenza vaccine in children in preventing influenza associated hospitalisation, 2018/19, England. (2020) (16)
Cross‐neutralisation of antibodies elicited by an inactivated split‐virion influenza A/Vietnam/1194/2004 (H5N1) vaccine in healthy adults against H5N1 clade 2 strains (2007) (16)
Hand and Respiratory Hygiene Practices and the Risk and Transmission of Human Coronavirus Infections in a UK Community Cohort (2020) (16)
Comparison of mucosal lining fluid sampling methods and influenza-specific IgA detection assays for use in human studies of influenza immunity. (2017) (16)
Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion (2020) (16)
Efficient boosting of the antiviral T cell response in B cell-depleted patients with autoimmune rheumatic diseases following influenza vaccination. (2013) (16)
Estimating the burden on general practitioner services in England from increases in respiratory disease associated with seasonal respiratory pathogen activity (2018) (16)
The inexact science of influenza prediction (2004) (16)
Outbreak of influenza A (H3N2) in a highly-vaccinated religious community: a retrospective cohort study. (2004) (15)
Author Correction: Progression of whole-blood transcriptional signatures from interferon-induced to neutrophil-associated patterns in severe influenza (2019) (15)
Detection of influenza A(H3N2) virus in children with suspected mumps during winter 2014/15 in England. (2015) (15)
SARS-CoV-2–specific memory B cells can persist in the elderly who have lost detectable neutralizing antibodies (2021) (14)
Favipiravir-resistant influenza A virus shows potential for transmission (2020) (14)
Programme of the Community Network of Reference Laboratories for Human Influenza to improve Influenza Surveillance in Europe. (2006) (14)
Importance of patient bed pathways and length of stay differences in predicting COVID-19 hospital bed occupancy in England (2021) (14)
Evaluation of the antiviral drug susceptibility of influenza viruses in Italy from 2004/05 to 2009/10 epidemics and from the recent 2009 pandemic. (2011) (14)
Serological surveillance of influenza in an English sentinel network: pilot study protocol (2019) (14)
Protection provided by influenza vaccine against influenza-related hospitalisation in ≥65 year olds: Early experience of introduction of a newly licensed adjuvanted vaccine in England in 2018/19. (2020) (14)
Influenza and other respiratory viruses surveillance in the United Kingdom: October 2003 to May 2004 (2004) (14)
Community Transmission and Viral Load Kinetics of SARS-CoV-2 Delta (B.1.617.2)Variant in Vaccinated and Unvaccinated Individuals (2021) (14)
A case of avian influenza A(H5N1) in England, January 2022 (2022) (14)
First external quality assurance of antibody diagnostic for SARS-new coronavirus (2005) (13)
Update on influenza and other viral pneumonias (2001) (13)
Viral Shedding in Recipients of Live Attenuated Influenza Vaccine in the 2016–2017 and 2017–2018 Influenza Seasons in the United Kingdom (2019) (13)
SARS-CoV-2 infection, antibody positivity and seroconversion rates in staff and students following full reopening of secondary schools in England: A prospective cohort study, September–December 2020 (2021) (13)
Neuraminidase inhibitors for influenza: a review and public health perspective in the aftermath of the 2009 pandemic (2013) (13)
SARS Antibody Testing in Children: Development of Oral Fluid Assays for IgG Measurements (2022) (13)
Severe acute respiratory syndrome revisited (2003) (12)
Multi-Centre Observational Study of Transplacental Transmission of Influenza Antibodies following Vaccination with AS03A-Adjuvanted H1N1 2009 Vaccine (2013) (12)
Population susceptibility to North American and Eurasian swine influenza viruses in England, at three time points between 2004 and 2011. (2013) (12)
Sudden acute respiratory syndrome (2003) (12)
Influenza surveillance in England and Wales: October 1997 to June 1998. (1998) (12)
Genome sequence analysis of Ebola virus in clinical samples from three British healthcare workers, August 2014 to March 2015. (2015) (12)
The burden of seasonal respiratory infections on a national telehealth service in England (2017) (12)
Experience with the clinical development of influenza vaccines for potential pandemics (2002) (12)
Hand Hygiene Practices and the Risk of Human Coronavirus Infections in a UK Community Cohort (2021) (12)
Postexposure Prophylaxis With rVSV-ZEBOV Following Exposure to a Patient With Ebola Virus Disease Relapse in the United Kingdom: An Operational, Safety, and Immunogenicity Report (2019) (12)
Proposal for Human Respiratory Syncytial Virus Nomenclature below the Species Level (2021) (11)
Lessons from the 1918 influenza (2007) (11)
Surveillance for antiviral resistance (2013) (11)
Antivirals in the 2009 pandemic – lessons and implications for future strategies (2013) (11)
Sustained detection of type 2 poliovirus in London sewage between February and July, 2022, by enhanced environmental surveillance (2022) (11)
Epidemiological and clinical characteristics of early COVID-19 cases, United Kingdom of Great Britain and Northern Ireland (2020) (11)
A randomised, partially observer blind, multicentre, head-to-head comparison of a two-dose regimen of Baxter and GlaxoSmithKline H1N1 pandemic vaccines, administered 21 days apart. (2010) (11)
Prospective Active National Surveillance of Preschools and Primary Schools for SARS-CoV-2 Infection and Transmission in England, June 2020: (sKIDs: COVID-19 Surveillance in School KIDs) (2021) (11)
Influenza surveillance in England and Wales: October 1995 to June 1996. (1996) (11)
Active and passive immunisation against respiratory syncytial virus (1999) (11)
Influenza activity in England and Wales: October 1998 to June 1999. (1999) (10)
Administration of AS03B-adjuvanted A(H1N1)pdm09 vaccine in children aged <3 years enhances antibody response to H3 and B viruses following a single dose of trivalent vaccine one year later. (2014) (10)
Polio eradication: next steps and future challenges (2018) (10)
Hepatitis C seroconversion in pregnancy (1994) (10)
Forecasting the 2017/2018 seasonal influenza epidemic in England using multiple dynamic transmission models: a case study (2019) (10)
Cross sectional investigation of a COVID-19 outbreak at a London Army barracks: Neutralising antibodies and virus isolation (2020) (10)
SIREN protocol: Impact of detectable anti-SARS-CoV-2 on the subsequent incidence of COVID-19 in 100,000 healthcare workers: do antibody positive healthcare workers have less reinfection than antibody negative healthcare workers? (2020) (10)
Laboratory containment for influenza A H5N1 virus: level 2, level 3, or level 3+? (1998) (10)
Cell culture for surveillance on influenza. (1999) (10)
Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study (2022) (10)
Antibody capture haemadherence tests for parvovirus B19-specific IgM and IgG. (1993) (9)
Use of Antiviral Drugs to Reduce Household Transmission of Pandemic (H1N1) 2009, United Kingdom (2011) (9)
Hepatitis A virus infection. Should susceptible homosexual men be offered immunization. (1993) (9)
Start of the influenza season 2008-9 in Europe - increasing influenza activity moving from West to East dominated by A(H3N2). (2009) (9)
COVID-19: public health management of the first two confirmed cases identified in the UK (2020) (8)
Unravelling the mysteries of influenza (2002) (8)
Influenza and Respiratory Virus Surveillance, Vaccine Uptake, and Effectiveness at a Time of Cocirculating COVID-19: Protocol for the English Primary Care Sentinel System for 2020-2021 (2020) (8)
Seasonal influenza surveillance and vaccine effectiveness at a time of co-circulating COVID-19: Oxford-Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) and Public Health England (PHE) protocol for winter 2020/21 (Preprint) (2020) (8)
Responses to live attenuated influenza vaccine in children vaccinated previously with Pandemrix (ASO3B adjuvanted pandemic A/H1N1pdm09). (2018) (8)
Emergence of a Novel Coronavirus (COVID-19): Protocol for Extending Surveillance Used by the Royal College of General Practitioners Research and Surveillance Centre and Public Health England (Preprint) (2020) (8)
Correction: Temporal Patterns of Influenza A and B in Tropical and Temperate Countries: What Are the Lessons for Influenza Vaccination? (2016) (8)
Influenza surveillance and laboratory diagnosis (2013) (8)
Public health implications of influenza B outbreaks in closed settings in the United Kingdom in the 2007/08 influenza season. (2008) (8)
Neuraminidase Inhibitor Susceptibility Network Position Statement: Antiviral Resistance in Influenza A/H5N1 Viruses (2005) (7)
The emergence of enterovirus D68 in England in autumn 2014 and the necessity for reinforcing enterovirus respiratory screening (2017) (7)
Influenza vaccine: going through a sticky patch (2017) (7)
Distinct clinical symptom patterns in patients hospitalised with COVID-19 in an analysis of 59,011 patients in the ISARIC-4C study (2022) (7)
Laboratory preparedness in EU/EEA countries for detection of novel avian influenza A(H7N9) virus, May 2013. (2014) (7)
Serological profile of first SARS-CoV-2 reinfection cases detected within the SIREN study (2021) (7)
Prophylactic efficacy of a human monoclonal antibody against MERS-CoV in the common marmoset (2019) (7)
Developing vaccines against potential pandemic influenza viruses (2001) (6)
Three years of low influenza activity--no reason for complacency. (2003) (6)
Novel coronavirus: how much of a threat? (2013) (6)
Virological self-sampling to monitor influenza antiviral susceptibility in a community cohort (2013) (6)
Joint ECDC CNRL and WHO/Europe briefing note on diagnostic preparedness in Europe for detection of avian influenza A(H7N9) viruses. (2013) (6)
Results from the WHO external quality assessment for the respiratory syncytial virus pilot, 2016‐17 (2020) (6)
Detection of varying influenza circulation within England in 2012/13: informing antiviral prescription and public health response. (2015) (6)
Clinical characteristics, predictors, and performance of case definition—Interim results from the WHO global respiratory syncytial virus surveillance pilot (2020) (6)
Automated digital reporting of clinical laboratory information to national public health surveillance systems, results of a EU/EEA survey, 2018 (2020) (5)
Antibody persistence and neutralising activity in primary school students and staff: Prospective active surveillance, June to December 2020, England (2021) (5)
Ethics versus evidence in influenza vaccination (2004) (5)
Mass testing after a single suspected or confirmed case of COVID-19 in London care homes, April–May 2020: implications for policy and practice (2021) (5)
Determining the Mutation Bias of Favipiravir in Influenza Using Next-generation Sequencing (2018) (5)
Influenza surveillance in England and Wales: October 1994 to June 1995. (1995) (5)
Emergence of the delta variant and risk of SARS-CoV-2 infection in secondary school students and staff: Prospective surveillance in 18 schools, England (2021) (5)
Assessment of the burden of influenza in children (2011) (5)
Possible contamination of organ preservation fluid with Bacillus cereus: the United Kingdom response. (2012) (5)
Household transmission of seasonal coronavirus infections: Results from the Flu Watch cohort study (2020) (5)
Do point-of-care tests (POCTs) offer a new paradigm for the management of patients with influenza? (2020) (5)
On the sensitivity and specificity of post-mortem upper respiratory tract testing for SARS-CoV-2 (2021) (5)
Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: A nested case-control within the SIREN study (2022) (5)
Estimation of Reduction in Influenza Vaccine Effectiveness Due to Egg-Adaptation Changes—Systematic Literature Review and Expert Consensus (2021) (5)
Design and Validation of an H 5 TaqMan Real-Time One-Step Reverse Transcription-PCR and Confirmatory Assays for Diagnosis and Verification of Influenza A Virus H 5 Infections in Humans (2007) (4)
The Oxford Royal College of General Practitioners Clinical Informatics Digital Hub: Protocol to Develop Extended COVID-19 Surveillance and Trial Platforms (Preprint) (2020) (4)
Inactivated pandemic 2009 H1N1 influenza A virus human vaccines have different efficacy after homologous challenge in the ferret model (2020) (4)
Impact of prior SARS-CoV-2 infection and COVID-19 vaccination on the subsequent incidence of COVID-19: a multicentre prospective cohort study among UK healthcare workers – the SIREN (Sarscov2 Immunity & REinfection EvaluatioN) study protocol (2022) (4)
Epidemiological features of a new strain of the influenza A virus--influenza A (H1N2) circulating in England and its public health implications. (2004) (4)
SARS-CoV-2-specific memory B cells can persist in the elderly despite loss of neutralising antibodies (2021) (4)
Influenza types and patient population (1995) (4)
A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern (2021) (4)
Use of traditional serological methods and oral fluids to assess immunogenicity in children aged 2–16 years after successive annual vaccinations with LAIV (2020) (4)
Sudden acute respiratory syndrome. May be a rehearsal for the next influenza pandemic [editorial] (2003) (3)
Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events (2016) (3)
Association of Age, Gender, Deprivation, Urbanicity, Ethnicity, and Smoking with a Positive Test for COVID-19 in an English Primary Care Surveillance Network: Cross Sectional Study of the First 500 Cases (2020) (3)
Can defective interfering RNAs affect the live attenuated influenza vaccine? - Authors' reply. (2017) (3)
Invasive Mycobacterium chimaera Infections and Heater–Cooler Devices in Cardiac Surgery (2020) (3)
Rapid community point-of-care testing for COVID-19 (RAPTOR-C19): protocol for a platform diagnostic study (2021) (3)
Household presentation of influenza and acute respiratory illnesses to a primary care sentinel network: retrospective database studies (2013–2018) (2020) (3)
Pre‐existing influenza‐specific nasal IgA or nasal viral infection does not affect live attenuated influenza vaccine immunogenicity in children (2020) (3)
Surveillance optimisation to detect poliovirus in the pre-eradication era: a modelling study of England and Wales (2020) (3)
Broadening symptom criteria improves early case identification in SARS-CoV-2 contacts (2021) (3)
Is the onset of influenza in the community age-related? (2016) (3)
The impact of social and physical distancing measures on COVID-19 activity in England: findings from a multi-tiered surveillance system (2021) (3)
Differences in nasal immunoglobulin A responses to influenza vaccine strains after live attenuated influenza vaccine (LAIV) immunization in children (2019) (3)
Flu vaccines: an annual challenge (2018) (3)
Uptake and impact of vaccinating primary school children against influenza: Experiences in the fourth season of the live attenuated influenza vaccination programme, England, 2016/2017 (2021) (3)
Secondary attack rates in primary and secondary school bubbles following a confirmed case: Active, prospective national surveillance, November to December 2020, England (2021) (3)
Shifty drifter up to no good. (2002) (2)
Evidence synthesis and decision modelling to support complex decisions: stockpiling neuraminidase inhibitors for pandemic influenza usage. (2016) (2)
Species Influenza A Viruses from Different Animal Assay for Detection and Differentiation of Combined PCR-Heteroduplex Mobility (2001) (2)
The role of genomics in understanding COVID-19 outbreaks in long term care facilities (2020) (2)
Informatics assisting influenza antiviral susceptibility monitoring in Europe (2008) (2)
Representativeness, Vaccination Uptake, and COVID-19 Clinical Outcomes 2020-2021 in the UK Oxford-Royal College of General Practitioners Research and Surveillance Network: Cohort Profile Summary (2022) (2)
The influenza virus. (1999) (2)
Identification of a new subtype of influenza virus A(H1N2) (2002) (2)
Quidel QuickVue Influenza A + B test (2014) (1)
Fifty years of influenza surveillance. (1999) (1)
Implementation and extended evaluation of the Euroimmun Anti-SARS-CoV-2 IgG assay and its contribution to the United Kingdom's COVID-19 public health response (2021) (1)
Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein (2020) (1)
Rapid influenza molecular testing in secondary care and influenza surveillance in England: Any impact? (2022) (1)
Evidence synthesis and decision modelling to support complex decisions: stockpiling neuraminidase inhibitors for pandemic influenza usage (2017) (1)
The antiviral action of amantadine and identification of a role for the M2 protein in influenza replication (1985) (1)
Genomic investigations of unexplained acute hepatitis in children. (2023) (1)
Strain designation for influenza viruses. (1999) (1)
Molecular methods for diagnosis of influenza (2001) (1)
Influenza, respiratory syncytial virus and SARS (2005) (1)
COVID-19 and SARS-CoV-2 Seropositivity in Children of Healthcare Workers in London (2020) (1)
Symptom‐based case definitions for COVID‐19: Time and geographical variations for detection at hospital admission among 260,000 patients (2022) (1)
influenza virus vaccine induces broadly reactive antibody responses 1 against H 7 N 9 in humans 2 (2014) (1)
Respiratory support in patients with severe COVID-19 in the International Severe Acute Respiratory and Emerging Infection (ISARIC) COVID-19 study: a prospective, multinational, observational study (2022) (1)
Enhanced surveillance and investigation of coronavirus: what is required? (2013) (1)
SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus [version 2; peer review: 1 approved] (2020) (1)
Comparing the incidence of common adverse events of interest following influenza vaccination in the first season adjuvanted trivalent immunisation was introduced: English sentinel network annual report paper 2018/19 (Preprint) (2020) (1)
WHO recommendations for influenza virus vaccine 2002/03 (2002) (1)
How long will vaccines continue to protect against COVID ? (2021) (1)
Influenza and Respiratory Syncytial Virus (2001) (1)
Risk factors and vectors for SARS-CoV-2 household transmission: a prospective, longitudinal cohort study (2023) (1)
Seropositivity and risk factors for SARS-CoV-2 infection in staff working in care homes during the COVID-19 pandemic (2020) (1)
Reply to Skowronski et al (2006) (1)
Influenza present: the impact of the 1999/2000 epidemic on morbidity and mortality in the UK (2001) (1)
Sero-Epidemiological Results in the Human Population Exposed to Highly Pathogenic Avian Influenza H5N1 Outbreak in a Large Poultry Farm in the East of England (2008) (1)
Emergence of Enterovirus D68 in England The emergence of enterovirus D68 in England in autumn 2014 and the necessity (2017) (1)
The Evaluation of Physical Activity Habits in North Italian People before and during COVID-19 Quarantine: A Pilot Study (2022) (1)
The Immunogenicity of a Cell‐derived H7N1 Split Influenza Virion Vaccine in Mice (2009) (1)
Evolutionary Dynamics of Local Pandemic H1N1/09 Influenza Lineages Revealed 1 (2011) (1)
Authors’ reply. Virological analysis of fatal influenza cases in the United Kingdom during the early wave of influenza in winter 2010/11 (2011) (0)
Implementation and Extended Evaluation of the Euroimmun Anti-SARS-CoV-2 IgG Assay and Its Contribution to the United Kingdom’s COVID-19 Public Health Response (2022) (0)
New perspectives on respiratory syncytial virus surveillance at the national level: lessons from the COVID-19 pandemic (2023) (0)
MERS-CoV S complex with human neutralizing LCA60 antibody Fab fragment (state 2) (2019) (0)
Integrated respiratory surveillance after the COVID-19 pandemic (2022) (0)
in the United Kingdom A(H1N1)pdm09 Influenza Virus in Humans Mutations during Circulation of Accumulation of Human-Adapting (2014) (0)
A comparison of two biological markers of recent hepatitis C virus ( HCV ) infection : implications for the monitoring of interventions and strategies to reduce HCV transmission among people who inject drugs (2018) (0)
The Burden of Seasonal Respiratory Pathogens on a New National Telehealth System (2016) (0)
Eurosurveillance - View Article (2012) (0)
MERS-CoV complex with human neutralizing LCA60 antibody Fab fragment (state 1) (2019) (0)
The Impact of Social and Physical Distancing Measures on COVID-19 Activity in England (2020) (0)
Cover (2020) (0)
The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection (2023) (0)
Rapid communications Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction (2012) (0)
Case report form, clinical study (2014) (0)
Antibody Persistence After Primary SARS-CoV-2 Infection and Protection Against Future Variants Including Omicron in Adolescents: National, Prospective Cohort Study. (2023) (0)
Future directions for the European influenza reference laboratory network in influenza surveillance. (2015) (0)
Influenza, respiratory syncytial virus and SARS (2005) (0)
Short term micronutrient supplementation in older institutionalised people does not improve the response to influenza vaccine — A randomised controlled trial (2003) (0)
Vector control to eliminate artemisinin resistant malaria in the Greater Mekong subregion (2014) (0)
Predictive accuracy of different clinical definitions of influenza in the community setting (2008) (0)
Revealed by Whole-Genome Analysis H1N1/2009 Influenza Virus Lineages Evolutionary Dynamics of Local Pandemic (2012) (0)
Systematic review and meta-analysis of near-patient tests for influenza A and B (2014) (0)
Adjuvanted or whole-virion vaccine for 2009 influenza A (H1N1) – Authors' reply (2011) (0)
Sample of WinBUGS code used (2014) (0)
Process outcomes and cost-effectiveness (2014) (0)
Cohort profile Cohort Profile: The Flu Watch Study the Flu Watch Group (2016) (0)
Streptomyces thermovulgaris Bacteremia in Crohn ’ s Disease Patient (2019) (0)
Oseltamivir is protective for in-patient mortality in PCR confirmed influenza B and influenza A(H3N2) infections in an historic cohort of 1,064 patients hospitalised during the 2016-17 and 2017-18 influenza seasons. (2023) (0)
Interpreting specific and general respiratory indicators in syndromic surveillance (2017) (0)
Inhibition of influenza virus replication by 1-aminoadamantane (1984) (0)
SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. Wellcome Open Research, 5, [181]. (2021) (0)
Design and Validation of an H5 TaqMan Real-Time One-Step Reverse Transcription-PCR and Conﬁrmatory Assays for Diagnosis and Veriﬁcation of Inﬂuenza A Virus H5 Infections in Humans (cid:1) (2007) (0)
, Maria disease in adolescents : matched cohort study Risk and protective factors for meningococcal (2006) (0)
Monographs in Virology Volume 27: Avian Influenza Edited by H.-D. Klenk, M. Matrosovich, and J. Stech Basel, Switzerland: S Karger AG, 2008. 294 pp., Illustrated. $249.00 (hardcover) (2009) (0)
811 'Flu vaccination in lung cancer patient — Is it effective? (1997) (0)
Ease and speed of use of point-of-care, molecular and traditional test methods for the diagnosis of respiratory infections (2014) (0)
A29 Genetic heterogeneity of influenza A (H3N2) viruses in the United Kingdom, 2016–8 (2019) (0)
Crystal structure of anti- SARS-CoV human neutralizing S230 antibody Fab fragment (2019) (0)
Late Ebola virus relapse causing meningoencephalitis-Suppl (2016) (0)
Assessing the Clinical and Socioeconomic Burden of Respiratory Syncytial Virus in Children Aged Under 5 Years in Primary Care: Protocol for a Prospective Cohort Study in England and Report on the Adaptations of the Study to the COVID-19 Pandemic (2022) (0)
Collection and transport of nasopharyngeal specimens (2014) (0)
Perspectives in interpandemic influenza. (2007) (0)
OP-IJEJ210080 1124..1133 (2021) (0)
Coinfection with Borrelia burgdorferi and Babesia microti: Bad or Worse? (2006) (0)
Background and rationale (2014) (0)
Correction: Corrigendum: Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events (2016) (0)
Results from the second WHO external quality assessment for the molecular detection of respiratory syncytial virus, 2019–2020 (2023) (0)
Comparison of SARS‐CoV‐2 neutralizing antibody testing of convalescent plasma donations in the Netherlands and England: A pilot study (2021) (0)
Antiviral drug resistance. (1998) (0)
Influenza in Europe Influenza in Europe (2012) (0)
Crystal structure of anti- MERS-CoV human neutralizing LCA60 antibody Fab fragment (2019) (0)
49 – Orthomyxoviruses: Influenza (2012) (0)
Adverse Events of Interest Following Influenza Vaccination in the First Season of Adjuvanted Trivalent Immunization: Retrospective Cohort Study (2022) (0)
Baillière's clinical infectious diseases. Herpes virus infections (1997) (0)
Summary of the protocol for the Three Winters Study (2014) (0)
Early Warning Surveillance for SARS-CoV-2 Omicron Variants, United Kingdom, November 2021–September 2022 (2022) (0)
ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19 (2022) (0)
Declining influenza activity in Europe while public concern over SARS has not increased general practice consultations for influenza-like illness or acute respiratory infections (2003) (0)
SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus [version 1; peer review: 1 approved with reservations] (2020) (0)
Inﬂuenza A antigen exposure selects dominant V β 17 (cid:1) TCR in human CD8 (cid:1) cytotoxic T cell responses (2001) (0)
Publications that were screened for the meta-analysis (2014) (0)
Europe's journal on infectious disease epidemiology, prevention and control (2012) (0)
BinaxNOW pneumococcal antigen test (2014) (0)
Different Efficacy of Inactivated Pandemic 2009 H1N1 Influenza A Virus Vaccines after Homologous Infection in Ferrets (2017) (0)
Author’s response: influenza-associated mortality oseltamivir: beware of misstepping into stepwise procedures (2019) (0)
Zika virus, the new kid on the block. (2016) (0)
Ease-of-use scores (2014) (0)

This paper list is powered by the following services:

Other Resources About Maria Zambon

en.wikipedia.org

Maria Zambon's Academic­Influence.com Rankings

Why Is Maria Zambon Influential?

Maria Zambon's Published Works

Published Works

Other Resources About Maria Zambon

Maria Zambon's AcademicInfluence.com Rankings